<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; section</title>
	<atom:link href="http://www.tapanray.in/tag/section/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Will ‘Patent Thicket’ Delay Biosimilar Drug Entry in India?</title>
		<link>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-patent-thicket-delay-biosimilar-drug-entry-in-india</link>
		<comments>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/#comments</comments>
		<pubDate>Mon, 22 Apr 2019 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Cyltezo]]></category>
		<category><![CDATA[delay]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[Losec]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Prilosec]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9496</guid>
		<description><![CDATA[Do pharma and biotech investors encourage companies indulging in ‘patent thicket?’ This question recently grabbed media headlines. On April 02, 2019, one such report brought out: AbbVie investors are calling for the Chair-CEO power split, flagging the CEO’s USD 4 million bonus payout, fueled &#8230; <a href="http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-patent-thicket-delay-biosimilar-drug-entry-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dwindling Drug Innovation: Declining Image: Unchanged Business And Advocacy Models</title>
		<link>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models</link>
		<comments>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/#comments</comments>
		<pubDate>Mon, 20 Feb 2017 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Chasing]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Dwinding]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rainbows]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8099</guid>
		<description><![CDATA[A report of ‘The United States International Trade Commission (USITC)’ released on December 22, 2014 suggested, if tariffs and investment restrictions were fully eliminated, and standards of IP protection were made comparable to the U.S and Western European levels, American &#8230; <a href="http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>At The Indian IPR Front: ‘Ground Control, There’s No Major Storm’</title>
		<link>http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=at-the-indian-ipr-front-ground-control-theres-no-major-storm</link>
		<comments>http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/#comments</comments>
		<pubDate>Mon, 05 Sep 2016 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[2016 Special 301 Report]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[4-5]]></category>
		<category><![CDATA[Arvind]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[G 20]]></category>
		<category><![CDATA[ground]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Major]]></category>
		<category><![CDATA[Niti Aayog]]></category>
		<category><![CDATA[Panagariya]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[September]]></category>
		<category><![CDATA[Sherpa]]></category>
		<category><![CDATA[storm]]></category>
		<category><![CDATA[Summit]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USIBC]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7794</guid>
		<description><![CDATA[The incessant pressure of the developing countries on India, from 2005 to date, to include various restrictive conditions in the Indian Patents Act 2005, still continue. This demand spans across the inclusion of even those provisions, which many experts term &#8230; <a href="http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>On Serious Healthcare, Some Bizarre Decisions</title>
		<link>http://www.tapanray.in/on-serious-healthcare-some-bizarre-decisions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=on-serious-healthcare-some-bizarre-decisions</link>
		<comments>http://www.tapanray.in/on-serious-healthcare-some-bizarre-decisions/#comments</comments>
		<pubDate>Mon, 15 Aug 2016 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA["Search Medicine Price"]]></category>
		<category><![CDATA['Pharma Jan Samadhan']]></category>
		<category><![CDATA[65%]]></category>
		<category><![CDATA[65(11)(c)]]></category>
		<category><![CDATA[Acts]]></category>
		<category><![CDATA[app]]></category>
		<category><![CDATA[Aushadhi]]></category>
		<category><![CDATA[bizarre]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[decision]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jan]]></category>
		<category><![CDATA[Mantri]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[original. substitution]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rules]]></category>
		<category><![CDATA[Samadhan]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[search]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Yojana’]]></category>
		<category><![CDATA[‘Pradhan]]></category>
		<category><![CDATA[‘Pradhan Mantri Jan-Aushadhi Yojana"]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7773</guid>
		<description><![CDATA[On August 04, 2016, it was widely reported by the media that the Union Minister of Chemicals and Fertilizers &#8211; Mr. Anant Kumar, would launch a new digital initiative of the National Pharmaceutical Pricing Authority (NPPA), named, &#8220;Search Medicine Price&#8221;, &#8230; <a href="http://www.tapanray.in/on-serious-healthcare-some-bizarre-decisions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/on-serious-healthcare-some-bizarre-decisions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patented Drugs: A Dangerous Pricing Trend Impacting Patient Access</title>
		<link>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patented-drugs-a-dangerous-pricing-trend-impacting-patient-access</link>
		<comments>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/#comments</comments>
		<pubDate>Mon, 11 Jul 2016 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[dangerous]]></category>
		<category><![CDATA[Daniel]]></category>
		<category><![CDATA[database]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[irresponsible]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[profits]]></category>
		<category><![CDATA[ptent]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Stone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[VL]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[Windfall]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7721</guid>
		<description><![CDATA[The upcoming trend of jaw dropping high prices for new patented drugs sends a ‘storm signal’ to many stakeholders, especially for its adverse impact on patient access. Even more intriguing, such high and insane prices are being fixed rather arbitrarily, &#8230; <a href="http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Patents Act To Prevail Undiluted…Finally</title>
		<link>http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-patents-act-to-prevail-undilutedfinally</link>
		<comments>http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/#comments</comments>
		<pubDate>Mon, 27 Jul 2015 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Birdie]]></category>
		<category><![CDATA[Carlos M. Correa]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[evergreening]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Joseph E. Stiglitz]]></category>
		<category><![CDATA[little]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Minister. Nirmala]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Nobel Laureates]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Sitharaman]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think Tank]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[undiluted]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6867</guid>
		<description><![CDATA[Curiously enough, what a little birdie told me just a couple of weeks ago, very similar to that I read in various media reports even less than a week later. It was related to a somewhat trepidatious national policy in the making on &#8230; <a href="http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-patents-act-to-prevail-undilutedfinally/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Playing Hardball, Riding the Horse of ‘Innovation’</title>
		<link>http://www.tapanray.in/playing-hardball-riding-the-horse-of-innovation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=playing-hardball-riding-the-horse-of-innovation</link>
		<comments>http://www.tapanray.in/playing-hardball-riding-the-horse-of-innovation/#comments</comments>
		<pubDate>Mon, 31 Mar 2014 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Bad]]></category>
		<category><![CDATA[beggars]]></category>
		<category><![CDATA[Ben]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[Doha]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Goldacre]]></category>
		<category><![CDATA[hardball]]></category>
		<category><![CDATA[horse]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[me-again]]></category>
		<category><![CDATA[me-too]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[playing]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ride]]></category>
		<category><![CDATA[riding]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[wishes]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5157</guid>
		<description><![CDATA[Media reports are now abuzz with various stories related to intense pressure being created by Big Pharma on the United States Government to declare India as a ‘Priority Foreign Country’ for initiating ‘Trade Sanctions’. As we know, ‘Priority Foreign Country’ &#8230; <a href="http://www.tapanray.in/playing-hardball-riding-the-horse-of-innovation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/playing-hardball-riding-the-horse-of-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does the Landmark Glivec Judgment Discourage Innovation in India?</title>
		<link>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-the-landmark-glivec-judgment-discourage-innovation-in-india</link>
		<comments>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/#comments</comments>
		<pubDate>Mon, 08 Apr 2013 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[191]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Case]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Cipal]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[gefitinib. Roche]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[highcourt]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[interpretation]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Janumet]]></category>
		<category><![CDATA[Januvia]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[knowledge]]></category>
		<category><![CDATA[landmark]]></category>
		<category><![CDATA[medicines. imatinib]]></category>
		<category><![CDATA[mesylate]]></category>
		<category><![CDATA[MSD]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[pegasys]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revocation]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[stutent]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[with]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[Zita]]></category>
		<category><![CDATA[Zita-Met]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2150</guid>
		<description><![CDATA[No, I do not think so. The 112 pages well articulated judgment of the Supreme Court of India delivered on April 1, 2013, does not even remotely discourage innovation in India, including much talked about ‘incremental innovation’. This landmark judgment &#8230; <a href="http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-the-landmark-glivec-judgment-discourage-innovation-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A brief history of the Indian Patent System from Indian Pharmaceutical Industry perspective, the concerns and opportunities.</title>
		<link>http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities</link>
		<comments>http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 00:30:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[brief]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[history]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=742</guid>
		<description><![CDATA[Although a comprehensive Act on Patents and Designs allowing product patents of drugs came into force in India in 1911, the first Patents Act of India was enacted in 1856.This Act gave a head start to the global pharmaceutical companies &#8230; <a href="http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The stormy debate on wrongful grant of pharma product patents – a countdown of the news events, for a quick perspective.</title>
		<link>http://www.tapanray.in/the-stormy-debate-on-wrongful-grant-of-pharma-product-patents-a-countdown-of-the-news-events-for-a-quick-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-stormy-debate-on-wrongful-grant-of-pharma-product-patents-a-countdown-of-the-news-events-for-a-quick-perspective</link>
		<comments>http://www.tapanray.in/the-stormy-debate-on-wrongful-grant-of-pharma-product-patents-a-countdown-of-the-news-events-for-a-quick-perspective/#comments</comments>
		<pubDate>Thu, 12 Mar 2009 16:55:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[countdown]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[news]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Quick]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Stormy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[wrongful]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=944</guid>
		<description><![CDATA[To give a quick perspective to this debate, I reckon, a countdown of five reported news events on the subject will be helpful. I start from February, 2009 and gradually go one year back, to February, 2008, to capture the &#8230; <a href="http://www.tapanray.in/the-stormy-debate-on-wrongful-grant-of-pharma-product-patents-a-countdown-of-the-news-events-for-a-quick-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-stormy-debate-on-wrongful-grant-of-pharma-product-patents-a-countdown-of-the-news-events-for-a-quick-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
